Nonsteroidal anti-inflammatory drugs, but not aspirin or acetaminophen, increase RCC risk
WEDNESDAY, Sept. 14 (HealthDay News) -- Use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs), but not aspirin and acetaminophen, is associated with an increased risk of renal cell cancer (RCC), with increased duration of use correlated with an elevated risk, according to a study published in the Sept. 12 issue of the Archives of Internal Medicine.
Eunyoung Cho, Sc.D., from Harvard Medical School in Boston, and colleagues investigated the correlation between analgesic use and RCC in 77,525 women followed up for 16 years, and 49,403 men followed up for 20 years. Data collected from the Health Professionals Follow-up Study in 1986 and from the Nurses' Health Study in 1990, and every two years thereafter were used to assess baseline and duration of analgesic use. A total of 333 RCC cases were identified.
The investigators found that aspirin and acetaminophen use did not correlate with RCC risk, but regular use of nonaspirin NSAIDs correlated with increased RCC risk (pooled multivariate relative risk, 1.51 at baseline). The absolute risk differences for users compared to nonusers of nonaspirin NSAIDs were 9.15 and 10.92 per 100,000 person-years for women and men, respectively. Compared to non-regular use of nonaspirin NSAIDs, the pooled multivariate relative risks for regular use were 0.81 (95 percent confidence interval [CI], 0.59 to 1.11) for less than four years of use; 1.36 (95 percent CI, 0.98 to 1.89) for four to less than 10 years of use; and 2.92 (95 percent CI, 1.71 to 5.01) for 10 or more years of use, which showed significance for the trend.
"Longer duration of use of nonaspirin NSAIDs may increase the risk of RCC," the authors write.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)